Nanomedicine represents a transformative approach to Alzheimer's disease (AD) therapy, offering innovative solutions to overcome the formidable challenges that have limited conventional treatment strategies. This emerging field leverages nanoscale materials and devices to enable precise diagnostic and therapeutic interventions that address the complex multifactorial pathophysiology of AD.
The blood-brain barrier (BBB) remains the primary obstacle in AD drug development, restricting approximately 98% of potential therapeutic molecules from reaching the brain [[1](https://doi.org/10.1016/j.addr.2024.115331). This selective interface, composed of tightly joined endothelial cells surrounded by pericytes and astrocyte end-feet, effectively excludes most large molecules and many small-molecule drugs despite their demonstrated efficacy in preclinical models.
Nanoparticle-based drug delivery systems offer a promising strategy to overcome this central obstacle through multiple mechanisms:
Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs. Their biocompatibility and ability to be surface-modified with targeting ligands make them versatile carriers for AD therapeutics. Recent advances have enabled liposomes to cross the BBB through surface decoration with transferrin, insulin, or apolipoprotein E peptides that engage native transport receptors [[1](https://doi.org/10.1016/j.addr.2024.115331).
Exosomes represent nature's own nanoscale delivery vehicles, being extracellular vesicles (30-150 nm) secreted by most cell types. These endogenous nanoparticles possess inherent BBB-penetrating capabilities and can be loaded with therapeutic cargo including small interfering RNA (siRNA), antisense oligonucleotides, and small molecules. Their ability to target specific cell types—particularly neurons, microglia, and astrocytes—makes them attractive for precision AD therapy [[1](https://doi.org/10.1016/j.addr.2024.115331).
Dendrimers are hyperbranched polymeric nanoparticles with precisely defined molecular architecture. Their multivalent surface allows attachment of multiple targeting ligands, therapeutic agents, and imaging probes simultaneously. Polyamidoamine (PAMAM) dendrimers have demonstrated ability to deliver drugs across the BBB, particularly when surface-modified with targeting moieties that engage BBB transport systems [[1](https://doi.org/10.1016/j.addr.2024.115331).
Carbon dots (CDs) are emergent carbon-based nanomaterials (typically <10 nm) with excellent photoluminescent properties, low toxicity, and facile surface functionalization. Their small size and tunable surface chemistry enable BBB penetration while their optical properties facilitate diagnostic imaging applications. Carbon dots can be designed as theranostic (therapeutic + diagnostic) agents combining therapy delivery with real-time imaging [[1](https://doi.org/10.1016/j.addr.2024.115331).
Advanced nanomedicine platforms incorporate stimulus-responsive release mechanisms that enable precise temporal and spatial control of drug delivery:
| Stimulus | Trigger | Application in AD |
|---|---|---|
| pH | Acidic endosomes/lysosomes | Lysosomal drug release |
| Enzymes | Proteases in pathological regions | Site-specific activation |
| Reactive oxygen species (ROS) | Elevated ROS in AD brain | Oxidative stress-responsive release |
| Light | Near-infrared irradiation | Externally controlled release |
| Ultrasound | Focused ultrasound | Temporary BBB opening |
These stimuli-responsive systems enable drug release specifically at pathological sites, minimizing off-target effects and reducing required doses [[1](https://doi.org/10.1016/j.addr.2024.115331).
A critical advantage of nanomedicine is the ability to address multiple AD pathogenic pathways simultaneously through multifunctional nanoplatforms:
Nanoparticles can be engineered to:
Nanotherapeutics targeting tau protein pathology include:
Nanomedicine approaches to cholinergic dysfunction include:
Addressing neuroinflammation in AD:
Nanoparticle approaches to oxidative stress:
Emerging approaches targeting the gut-brain axis:
Beyond therapeutics, nanotechnology enables advanced AD diagnostics:
Nanosensors offer enhanced sensitivity for detecting AD-related biomarkers:
Nanoparticle-enhanced imaging modalities:
Emerging wearable technologies incorporating nanoscale sensors enable continuous monitoring of:
Despite compelling preclinical evidence, significant hurdles impede clinical translation of AD nanomedicines [[1](https://doi.org/10.1016/j.addr.2024.115331) [[2](https://doi.org/10.1016/j.jconrel.2024.12.045):
The field of AD nanomedicine is evolving toward:
Nanomedicine offers a transformative paradigm for AD treatment by addressing the fundamental delivery challenges that have limited conventional therapeutics. Through sophisticated nanocarrier platforms, stimuli-responsive release systems, and multi-target strategies, nanotechnology enables the simultaneous addressing of amyloid pathology, tauopathy, cholinergic dysfunction, neuroinflammation, and oxidative stress. While significant challenges remain in clinical translation, the compelling preclinical evidence positions AD nanomedicine as a promising avenue for developing effective disease-modifying therapies.